Correlation of safety and efficacy of atezolizumab therapy across indications
Background The association between safety and efficacy of immune checkpoint inhibitors is known, but the correlation between severity and impact of specific organ involvement by immune-related adverse events (irAE) and cancer outcomes is poorly understood. Most irAEs are mild-to-moderate but severe...
Saved in:
| Main Authors: | Jarushka Naidoo, Guru Sonpavde, Mark A Socinski, Rajat Mohindra, Corey Carter, Laurent Essioux, Gonzalo Durán-Pacheco, G Scott Chandler, Vidya Maiya, Javier Puente, Jose Vicente Cardona |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/12/11/e010158.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Early dynamics of clinical and laboratory parameters predict primary refractory disease in patients with metastatic urothelial carcinoma receiving atezolizumab
by: Guru Sonpavde, et al.
Published: (2025-05-01) -
Response to: Correspondence on “Early dynamics of clinical and laboratory parameters predict primary refractory disease in patients with metastatic urothelial carcinoma receiving atezolizumab” by Gao et al
by: Guru Sonpavde, et al.
Published: (2025-06-01) -
Vaccine approaches to treat urothelial cancer
by: Giulia Claire Giudice, et al.
Published: (2024-12-01) -
Atezolizumab in the treatment of small cell lung cancer
by: Kacper Ordon, et al.
Published: (2025-06-01) -
Atezolizumab‐Induced Immune‐Related Pneumonia on Rounded Atelectasis
by: Satoru Yanagisawa, et al.
Published: (2024-09-01)